Article
Pharmacology & Pharmacy
Marie-Sophie Minot-This, Pascaline Boudou-Rouquette, Anne Jouinot, Sixtine de Percin, David Balakirouchenane, Nihel Khoudour, Camille Tlemsani, Jonathan Chauvin, Audrey Thomas-Schoemann, Francois Goldwasser, Benoit Blanchet, Jerome Alexandre
Summary: This study aimed to define the specific threshold of Pazopanib (PAZ) trough concentration associated with better progression-free survival in soft tissue sarcoma patients. The results showed that PAZ C-min < 27 mg/L was independently associated with a risk of progression at 3 months, and a higher average of PAZ C-min was associated with a higher risk of grade 3-4 toxicities.
Article
Oncology
Ahmet Bilici, Sinan Koca, Mustafa Karaagac, Sabin Goktas Aydin, Emrah Eraslan, Muhammed Ali Kaplan, Birol Ocak, Sema Sezgin Goksu, Semra Paydas, Fahri Akgul, Sumeyye Derin, Yakup Ergun, Emre Yekeduz, Cihan Erol, Deniz Tataroglu Ozyukseler, Atike Gokcen Demiray, Mustafa Karaca, Zeynep Gulsum Guc, Serkan Menekse, Havva Yesil Cinkir, Ozge Gumusay, Abdullah Sakin, Ozlem Ozkul, Hacer Demir, Dilek Erdem, Mehmet Besiroglu, Olcun Umit Unal, Ramazan Acar, Lokman Koral, Suleyman Sahin, Teoman Sakalar, Aykut Bahceci, Ahmet Ozveren, Ulug Mutlu Gunaydin, Mehmet Metin Seker, Veli Sunar, Pinar Dal, Mehmet Artac, Serdar Turhal
Summary: This study retrospectively analyzed the medical records of patients with non-adipocytic metastatic soft tissue sarcoma treated with pazopanib in 37 oncology clinics in Turkey. The results showed that pazopanib is effective and well-tolerated in the treatment of this disease, with better outcomes observed when used earlier and in patients with good performance status.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Do Weon Lee, Han-Soo Kim, Ilkyu Han
Summary: The study found that actual 5-year survival in stage III soft tissue sarcoma patients is associated with tumor size, histological grade, and ASA score. Nevertheless, the majority of long-term survivors still exhibit factors of poor prognosis.
Article
Oncology
Sang Kyum Kim, Jee Hung Kim, Seung Hyun Kim, Young Han Lee, Jung Woo Han, Wooyeol Baek, Ha Young Woo, Min Kyung Jeon, Hyo Song Kim
Summary: Based on the evaluation of PD-L1 expression in tumor tissues from advanced STS patients treated with pazopanib, it was found that PD-L1 expression can help predict the clinical outcome of pazopanib therapy, with PD-L1 positive tumors showing poorer response to treatment.
Article
Oncology
Zhichao Liao, Chao Zhang, Tielong Yang, Haotian Liu, Songwei Yang, Ting Li, Ruwei Xing, Sheng Teng, Yun Yang, Jun Zhao, Gang Zhao, Xu Bai, Lei Zhu, Jilong Yang
Summary: This study confirms the efficacy and safety of chemotherapy combined with Endostar in stage IV soft tissue sarcoma, and identifies undifferentiated polymorphic sarcoma (UPS) as a potential subtype that benefits from this combined treatment.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Tomoki Nakamura, Akihiro Sudo
Summary: Trabectedin is a safe and effective therapeutic option for patients with advanced STS. While it may be effective as first-line treatment in selected patients, doxorubicin remains the preferred choice for locally advanced or metastatic STS.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Alessandra Buja, Massimo Rugge, Matteo Barillaro, Andrea Miatton, Saveria Tropea, Claudia Cozzolino, Manuel Zorzi, Antonella Vecchiato, Paolo Del Fiore, Antonella Brunello, Vincenzo Baldo, Carlo Riccardo Rossi, Simone Mocellin
Summary: This study aimed to compare the pathological and clinical features of retroperitoneal soft-tissue sarcomas (RPS) and non-RPS, and analyze if the hazard ratio for short-term mortality differs between RPS and non-RPS after adjusting for baseline differences. The analysis found that RPS accounted for 22.8% of cases, with different characteristics compared to non-RPS. The retroperitoneum site was an independent prognostic factor associated with worse overall survival in sarcoma patients.
Article
Oncology
Yasuyoshi Sato, Kenji Nakano, Xiaofei Wang, Naoki Fukuda, Tetsuya Urasaki, Akihiro Ohmoto, Naomi Hayashi, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, Masanori Saito, Yusuke Minami, Keiko Hayakawa, Yuki Funauchi, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Shunji Takahashi
Summary: The second-line systematic therapy options for soft-tissue sarcoma (STS) have remained unchanged for decades, but challenges with molecular-targeted treatments led to the approval of pazopanib. This study investigated the use of the neutrophil-to-lymphocyte ratio (NLR) as a predictor for the efficacy and prognosis of pazopanib in STS patients. The findings suggest that baseline NLR may predict the efficacy and patient prognosis of pazopanib for STS.
Article
Oncology
Christoph E. Heilig, Andreas Lassmann, Sadaf S. Mughal, Andreas Mock, Sebastian Pirmann, Veronica Teleanu, Marcus Renner, Carolin Andresen, Bruno C. Kohler, Bogac Aybey, Sebastian Bauer, Jens T. Siveke, Rainer Hamacher, Gunnar Folprecht, Stephan Richter, Evelin Schrock, Christian H. Brandts, Marit Ahrens, Peter Hohenberger, Gerlinde Egerer, Thomas Kindler, Melanie Boerries, Anna L. Illert, Nikolas von Bubnoff, Leonidas Apostolidis, Philipp J. Jost, C. Benedikt Westphalen, Wilko Weichert, Ulrich Keilholz, Frederick Klauschen, Katja Beck, Ulrike Winter, Daniela Richter, Lino Mohrmann, Michael Bitzer, Klaus Schulze-Osthoff, Benedikt Brors, Gunhild Mechtersheimer, Simon Kreutzfeldt, Christoph Heining, Daniel B. Lipka, Albrecht Stenzinger, Richard F. Schlenk, Peter Horak, Hanno Glimm, Daniel Hubschmann, Stefan Frohling
Summary: The expression levels of NTRK3, IGF1R, and KDR genes are associated with progression-free survival in patients with sarcoma treated with pazopanib. A pazopanib efficacy predictor can be developed based on the expression levels of these genes to accurately predict treatment outcomes for patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Maria L. Inchaustegui, Kelly Kon-Liao, Kim Ruiz-Arellanos, George Aquilino E. Silva, Marcos R. Gonzalez, Juan Pretell-Mazzini
Summary: This systematic review analyzed the treatment options and outcomes for patients with radiation-induced soft tissue sarcomas (RISs). The most common treatment for RISs was surgery, with chemotherapy and radiotherapy used less frequently. Patients with RISs had a low 5-year survival rate, and high rates of local recurrence and cancer spreading.
Article
Biochemistry & Molecular Biology
William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang
Summary: Immunotherapy in soft tissue sarcoma has become a popular and promising therapeutic strategy, with immune checkpoint inhibitors showing effectiveness in certain subtypes. Combination therapies have also shown enhanced response rates.
Article
Biotechnology & Applied Microbiology
Kang-Wen Xiao, Zhi-Qiang Yang, Xin Yan, Zhi-Bo Liu, Min Yang, Liang-Yu Guo, Lin Cai
Summary: By analyzing the characteristics and patterns of m6A modification in soft tissue sarcoma (STS), this study identified two different modification patterns and found that m6A cluster A had better clinical outcomes and lower immune/stromal scores compared to m6A cluster B. Additionally, the m6Ascore effectively predicted the characteristics and prognosis of STS, as well as the outcome of PD-1/PD-L1 blockade immunotherapy.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Oncology
Neeta Somaiah, Brian Andrew Van Tine, Amy E. Wahlquist, Mohammed M. Milhem, Elizabeth G. Hill, Elizabeth Garrett-Mayer, Kent E. Armeson, Scott M. Schuetze, Christian F. Meyer, Daniel Y. Reuben, Anthony D. Elias, William L. Read, Sant P. Chawla, Andrew S. Kraft
Summary: The study demonstrated that the combination of gemcitabine plus pazopanib (G+P) is a safe and effective alternative treatment for patients with advanced nonadipocytic soft-tissue sarcoma (STS). G+P showed similar efficacy and lower rates of adverse events compared to gemcitabine plus docetaxel (G+T).
Article
Oncology
Laura Molenaar-Kuijsten, Milan van Meekeren, Remy B. Verheijen, Judith V. M. G. Bovee, Marta Fiocco, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Aisha B. Miah, Hans Gelderblom, Rick L. M. Haas, Neeltje Steeghs
Summary: The study found a modest correlation between tumor concentrations and plasma levels of pazopanib, but no correlation was found between tumor concentrations and efficacy. Factors such as tumor heterogeneity and timing of the biopsy procedure could explain the lack of correlation.
Article
Oncology
Jung Yong Hong, Hee Jin Cho, Kum-Hee Yun, Young Han Lee, Seung Hyun Kim, Wooyeol Baek, Sang Kyum Kim, Yurimi Lee, Yoon-La Choi, Minsuk Kwon, Hyo Song Kim, Jeeyun Lee
Summary: This study investigated the molecular determinants of pazopanib response in refractory soft tissue sarcoma patients. It identified CDK4 amplification as a predictor of poor response and shorter progression-free survival. Additionally, the combination of pazopanib and durvalumab showed efficacy in patients with high immune/stromal cell infiltration and increased CD19 expression.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Tatsuki Ikoma, Mototsugu Shimokawa, Masahito Kotaka, Toshihiko Matsumoto, Hiroki Nagai, Shogen Boku, Nobuhiro Shibata, Hisateru Yasui, Hironaga Satake
Summary: In this study, it was found that CRC patients with KRAS non-Exon2 and NRAS mutations had shorter survival time compared to those with wild-type RAS, and significantly shorter overall survival than patients with KRAS Exon2 mutations in Japan.
Meeting Abstract
Oncology
Shogen Boku, Motoki Watanabe, Mamiko Sukeno, Takeshi Yaoi, Kiichi Hirota, Mahiro Iizuka, Kyoko Itoh, Yoshihiro Sowa, Yosuke Iizumi, Mitsuharu Masuda, Takumi Narita, Takahiro Hamoya, Toshiyuki Sakai, Michihiro Mutoh
ANNALS OF ONCOLOGY
(2021)
Meeting Abstract
Oncology
Nobuhiro Shibata, Shogen Boku, Yoshimi Shinomiya, Hironaga Satake
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Meiko Nishimura, Hideki Sakai, Takuma Onoe, Shogen Boku, Takaaki Yokoyama, Genmu Kadokura, Satoshi Morita, Noriyuki Katsumata, Koji Matsumoto
Summary: The 4-step, 2-hour carboplatin desensitization protocol is safe and feasible for treating ovarian cancer patients. Patients require careful monitoring and rapid response to hypersensitivity reactions, especially during the administration of undiluted solutions.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Terufumi Yoshida, Hisanori Miki, Hironaga Satake, Toshinori Kobayashi, Yuuki Matsumi, Madoka Hamada, Shogen Boku, Nobuhiro Shibata, Mitsuaki Ishida, Mitsugu Sekimoto
Summary: Preoperative treatment with pembrolizumab resulted in pathological complete response in a case of MSI-H clinical T4b ascending colon cancer, showing potential efficacy in locally advanced colon cancer cases with microsatellite instability-high status.
CASE REPORTS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Toshihiko Matsumoto, Shogo Yamamura, Tatsuki Ikoma, Yusuke Kurioka, Keitaro Doi, Shogen Boku, Nobuhiro Shibata, Hiroki Nagai, Takanobu Shimada, Takao Tsuduki, Takehiko Tsumura, Masahiro Takatani, Hisateru Yasui, Hironaga Satake
Summary: This study analyzed the data of patients with HER2-positive advanced gastric cancer who received trastuzumab deruxtecan (T-DXd) and found that pre-administration of immune checkpoint inhibitors and a sufficiently long trastuzumab-free interval may be predictive factors of T-DXd efficacy.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Tomohisa Yamamoto, Sohei Satoi, So Yamaki, Daisuke Hashimoto, Mitsuaki Ishida, Tsukasa Ikeura, Satoshi Hirooka, Yuki Matsui, Shogen Boku, Shinji Nakayama, Koh Nakamaru, Nobuhiro Shibata, Utae Katsushima, Mitsugu Sekimoto
Summary: Pancreatic ductal adenocarcinoma (PDAC) with peritoneal dissemination is a highly lethal disease. Recent studies have shown promising activity of intraperitoneal chemotherapy with paclitaxel (i.p.-PTX) in PDAC patients with peritoneal dissemination. This retrospective comparative study compared the clinical efficacy of i.p.-PTX combined with systemic chemotherapy versus standard systemic chemotherapy in PDAC patients. The results show that i.p.-PTX therapy improved survival in PDAC patients with peritoneal dissemination, and conversion surgery enhanced survival in patients with favorable responses to chemotherapy.
Article
Oncology
Tatsuki Ikoma, Mototsugu Shimokawa, Toshihiko Matsumoto, Shogen Boku, Tomoyo Yasuda, Nobuhiro Shibata, Yusuke Kurioka, Masahiro Takatani, Tetsuji Nobuhisa, Tsutomu Namikawa, Hiroyuki Kitagawa, Kazuhiro Hanazaki, Keitaro Doi, Takanobu Shimada, Takehiko Tsumura, Hiroyuki Marusawa, Seichiro Kanaya, Shuko Morita, Tetsurou Inokuma, Hiroki Nagai, Hisateru Yasui, Hironaga Satake
Summary: This study aimed to investigate the usefulness of inflammatory prognostic factors in predicting the prognosis of patients with esophageal squamous cell carcinoma (ESCC) treated with nivolumab monotherapy. The results showed that inflammatory prognostic factors were useful in predicting prognosis, especially for patients with CAR < 0.62.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Gastroenterology & Hepatology
Daisuke Hashimoto, Sohei Satoi, Tomohisa Yamamoto, So Yamaki, Mitsuaki Ishida, Satoshi Hirooka, Nobuhiro Shibata, Shogen Boku, Tsukasa Ikeura, Mitsugu Sekimoto
Summary: This study investigated patients with multifocal intraductal papillary mucinous neoplasms (IPMNs) and found that the presence of multiple cysts in the pancreas does not affect patient survival. When treating these patients, each cyst should be evaluated individually for the presence of features associated with malignancy.
Review
Oncology
Shogen Boku, Hironaga Satake, Takashi Ohta, Seiichiro Mitani, Kentaro Kawakami, Yozo Suzuki, Toshihiko Matsumoto, Tetsuji Terazawa, Eiki Yamazaki, Hiroko Hasegawa, Tatsuki Ikoma, Mamoru Uemura, Toshifumi Yamaguchi, Atsushi Naito, Yasunobu Ishizuka, Yukinori Kurokawa, Daisuke Sakai, Hisato Kawakami, Toshio Shimokawa, Toshimasa Tsujinaka, Takeshi Kato, Taroh Satoh, Yoshinori Kagawa
Summary: The BRAF V600E mutation is a poor prognostic factor in colorectal cancer, and there are no clear recommendations for first line therapy for patients with this mutation. A recent study showed that a combination of encorafenib, binimetinib and cetuximab had a higher response rate compared to standard chemotherapy. The ongoing TRESBIEN study aims to evaluate the effectiveness of this combination therapy for patients with early recurrent BRAF V600E-mutated colorectal cancer.
Article
Gastroenterology & Hepatology
Daisuke Hashimoto, Tatsuma Sakaguchi, Sohei Satoi, Tomohisa Yamamoto, So Yamaki, Mitsuaki Ishida, Yuki Matsui, Nobuhiro Shibata, Shogen Boku, Utae Katsushima, Tsukasa Ikeura, Mitsugu Sekimoto
Summary: This study aimed to compare the characteristics and prognoses of patients with occult metastases (OM) and radiologically defined metastases (RM) of pancreatic ductal adenocarcinoma (PDAC), and to establish a treatment strategy for PDAC patients with OM. The study found that the median overall survival of OM was significantly better than that of RM, but general and nutritional statuses, primary tumor size and CA19-9, conversion surgery and multiple lines of chemotherapy were independent predictors, while the type of metastasis (OM vs RM) was not an independent predictor.
Article
Medicine, General & Internal
Tatsuki Ikoma, Toshihiko Matsumoto, Shogen Boku, Tomoyo Yasuda, Masataka Masuda, Takashi Ito, Koh Nakamaru, So Yamaki, Shinji Nakayama, Daisuke Hashimoto, Tomohisa Yamamoto, Nobuhiro Shibata, Tsukasa Ikeura, Makoto Naganuma, Sohei Satoi, Takayasu Kurata
Summary: We retrospectively analyzed the efficacy and safety data of nanoliposomal irinotecan combined with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) in elderly patients with unresectable pancreatic cancer. There were no significant differences in median overall survival (OS) and progression-free survival (PFS) between elderly and non-elderly patients. The C-reactive protein/albumin ratio (CAR) and neutrophil/lymphocyte ratio (NLR) could be potential indicators to determine eligibility for nal-IRI+5-FU/LV.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Toshihiko Matsumoto, Shogo Yamamura, Tatsuki Ikoma, Yusuke Kurioka, Keitaro Doi, Tomoyo Yasuda, Shogen Boku, Takashi Kawai, Nobuhiro Shibata, Hiroki Nagai, Takao Tsuduki, Takanobu Shimada, Yusuke Matsumoto, Takehiko Tsumura, Masahiro Takatani, Hisateru Yasui, Hironaga Satake
Summary: We retrospectively analyzed the data of patients with advanced gastric cancer receiving trifluridine/tipiracil (FTD/TPI) treatment. The results showed that in real-world clinical practice, FTD/TPI has manageable toxicity and comparable effectiveness to late-line chemotherapy in patients with advanced gastric cancer.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY
(2022)
Meeting Abstract
Oncology
Shogen Boku, Motoki Watanabe, Mahiro Iizuka, Yoshihiro Sowa, Mitsuharu Masuda, Yosuke Iizumi, Takumi Narita, Hironaga Satake, Toshiyuki Sakai, Michihiro Mutoh
Meeting Abstract
Oncology
Motoki Watanabe, Keiko Miyamoto, Shogen Boku, Koichi Sakaguchi, Tetsuya Taguchi, Yoshihiro Sowa, Yosuke Iizumi, Mitsuharu Masuda, Takumi Narita, Takahiro Hamoya, Toshiyuki Sakai, Michihiro Mutoh